FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
Related Articles
Bench to Bedside Chat- “Drug Development for Economically Infeasible Indications”
This video discusses FDA programs that are designed to support rare disease product development.
NatureMills US Inc. Issues Allergy Alert on Undeclared Wheat, Milk, and Sesame in Rice Mixes, Soups, Spice Mixes, Porridge Mix, Papads and Vadam Products
NatureMills US Inc., based in Prosper, Texas, is recalling select products that were sold between December 1, 2023, and May 10, 2025, due to undeclared…
HHS, FDA Issue RFI on Deregulatory Plan to Lower Costs and Empower Providers
HHS, FDA Issue RFI on Deregulatory Plan to Lower Costs and Empower Providers
Ariana Sweets Inc. Issues Allergy Alert on Undeclared Sesame and Wheat in AFGHANI CORN BREAD (“Doda”)
May, 13, 2025, Ariana Sweets Inc. of Fremont, CA is recalling AFGHANI CORN BREAD “Doda” manufactured prior to 4/24/2025, because it may contain undeclared sesame…
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCL
On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.)
Childhood Cancers
Information about the common types of pediatric cancers, the latest treatments, where to go for treatment, and where to find information about coping and survivorship.
FDA approves belzutifan for pheochromocytoma or paraganglioma
On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCL
On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.)
FDA approves belzutifan for pheochromocytoma or paraganglioma
On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older